Patents by Inventor Catherine J. Pachuk
Catherine J. Pachuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10982212Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.Type: GrantFiled: April 27, 2018Date of Patent: April 20, 2021Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
-
Publication number: 20190100757Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.Type: ApplicationFiled: April 27, 2018Publication date: April 4, 2019Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
-
Patent number: 9982263Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.Type: GrantFiled: October 23, 2015Date of Patent: May 29, 2018Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
-
Publication number: 20160208261Abstract: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell.Type: ApplicationFiled: November 19, 2015Publication date: July 21, 2016Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Chandrasekhar Satishchandran, Catherine J. Pachuk
-
Publication number: 20160177310Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.Type: ApplicationFiled: October 23, 2015Publication date: June 23, 2016Inventors: Catherine J. Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
-
Patent number: 9200281Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.Type: GrantFiled: October 1, 2013Date of Patent: December 1, 2015Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
-
Publication number: 20150093824Abstract: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell.Type: ApplicationFiled: October 3, 2014Publication date: April 2, 2015Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Chandrasekhar SATISHCHANDRAN, Catherine J. PACHUK
-
Publication number: 20140273213Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.Type: ApplicationFiled: October 1, 2013Publication date: September 18, 2014Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
-
Patent number: 8575327Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.Type: GrantFiled: December 12, 2005Date of Patent: November 5, 2013Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Catherine J. Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
-
Patent number: 8350021Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.Type: GrantFiled: June 10, 2004Date of Patent: January 8, 2013Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Catherine J. Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Jr., Liat Mintz
-
Patent number: 8299042Abstract: The present invention provides methods of post-transcriptional gene silencing which involve the use of a first dsRNA having substantial sequence identity to a target nucleic acid and a short, second dsRNA which inhibits dsRNA-mediated toxicity. These methods can be used to prevent or treat a disease or infection by silencing a gene associated with the disease or infection. The invention also provides methods for identifying nucleic acid sequences that modulate a detectable phenotype, including the function of a cell, the expression of a gene, or the biological activity of a target polypeptide.Type: GrantFiled: September 24, 2008Date of Patent: October 30, 2012Assignee: Alnylam Pharmaceuticals, Inc.Inventor: Catherine J. Pachuk
-
Publication number: 20120035240Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.Type: ApplicationFiled: December 12, 2005Publication date: February 9, 2012Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: CATHERINE J. PACHUK, CHANDRASEKHAR SATISHCHANDRAN, VINCENT R. ZURAWSKI, JR., LIAT MINTZ
-
Publication number: 20120028348Abstract: Expression constructs comprising at least two different RNA polymerase III promoters, wherein each promoter is operably linked to a nucleic acid sequence encoding an RNA effector molecule, are disclosed herein. Further provided are expression constructs comprising multiple polymerase III promoters operably linked to sequences encoding short hairpin RNA molecules, which may comprise single and/or multiple fingers. The provided constructs are useful for in vivo delivery of RNA molecules effective in gene silencing, including of viral genes including HBV and HCV.Type: ApplicationFiled: June 15, 2011Publication date: February 2, 2012Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Catherine J. Pachuk, Daniel Edward McCallus, Chandrasekhar Satishchandran, Martin D. Sigg, JR.
-
Publication number: 20110245329Abstract: The present invention relates to novel double-stranded RNA (dsRNA) structures and dsRNA expression constructs, methods for generating them, and methods of utilizing them for silencing genes. Desirably, these methods specifically inhibit the expression of one or more target genes in a cell or animal (e.g., a mammal such as a human) without inducing toxicity. These methods can be used to prevent or treat a disease or infection by silencing a gene associated with the disease or infection. The invention also provides methods for identifying nucleic acid sequences that modulate a detectable phenotype, such as the function of a cell, the expression of a gene, or the biological activity of a target polypeptide.Type: ApplicationFiled: May 9, 2011Publication date: October 6, 2011Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Catherine J. Pachuk, Chandrasekhar Satishchandran, Daniel Edward McCallus
-
Publication number: 20110223634Abstract: The invention features methods of analyzing the kinetics properties of transfection reactions. Also featured are methods for creating structural promoters which are effectively unregulated by enhancers and repressors. The structural promoters are significantly more active than the native promoter sequences upon which they are based.Type: ApplicationFiled: February 8, 2011Publication date: September 15, 2011Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Catherine J. Pachuk, C. Satishchandran
-
Patent number: 7985581Abstract: Expression constructs comprising at least two different RNA polymerase III promoters, wherein each promoter is operably linked to a nucleic acid sequence encoding an RNA effector molecule, are disclosed herein. Further provided are expression constructs comprising multiple polymerase III promoters operably linked to sequences encoding short hairpin RNA molecules, which may comprise single and/or multiple fingers. The provided constructs are useful for in vivo delivery of RNA molecules effective in gene silencing, including of viral genes including HBV and HCV.Type: GrantFiled: August 23, 2005Date of Patent: July 26, 2011Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Catherine J. Pachuk, Daniel E. McCallus, Chandrasekhar Satishchandran, Martin D. Sigg, Jr.
-
Publication number: 20110105593Abstract: Vectors expressing multiple microRNA (miRNA)-formatted interfering RNAs from a single transcript are disclosed and methods of using the same to inhibit expression of one or more target genes.Type: ApplicationFiled: June 3, 2010Publication date: May 5, 2011Inventors: Laura Steel, Catherine J. Pachuk
-
Patent number: 7897382Abstract: The invention features methods of analyzing the kinetics properties of transfection reactions. Also featured are methods for creating structural promoters which are effectively unregulated by enhancers and repressors. The structural promoters are significantly more active than the native promoter sequences upon which they are based.Type: GrantFiled: February 20, 2008Date of Patent: March 1, 2011Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Catherine J. Pachuk, Chandrasekhar Satishchandran
-
Publication number: 20100190842Abstract: The invention provides isolated RNA molecules containing a stretch of nucleotides from a conserved Influenza sequence, and provides complementary RNA molecules thereto. The RNA molecules of the invention are also substantially non-homologous to human sequences. The RNA molecules of the invention include double-stranded RNAs comprising a first region that is a conserved Influenza sequence, and a second region that is at least substantially complementary to the first region. Such double-stranded RNAs include single short hairpin RNAs (shRNAs) as well as multi-target hairpin RNAs containing a plurality, or several, stem-loop structures. The present invention further provides expression constructs that provide for expression of one, or a plurality, of RNA molecules of the invention. The RNA molecules, expression constructs, and compositions of the present invention find use in reducing levels of Influenza A RNA, in reducing Influenza A virus titer, and in treating or preventing Influenza virus infection.Type: ApplicationFiled: April 14, 2008Publication date: July 29, 2010Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Catherine J. Pachuk, Daniel E. McCallus
-
Publication number: 20100172976Abstract: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell.Type: ApplicationFiled: December 18, 2009Publication date: July 8, 2010Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Chandrasekhar Satishchandran, Catherine J. Pachuk